Strategic Financing Advisory in Life Sciences
Healthcare & Life Sciences is part of FCF’s DNA. We pair unique industry experience with extensive financing track record. FCF has established itself as a leading Healthcare & Life Sciences financing expert in Europe. Together with our very hands-on approach in company advisory and our experienced Healthcare & Life Sciences Advisory Board we find the perfect individual financing solution for your company. At FCF we have helped many Healthcare- and Life Sciences companies to translate their innovative- and unique technologies into successful financing stories.
We have a broad sector focus and aim to represent unique companies with a clear patient benefit in the areas of:- Pharmaceuticals & Biotechnology
- Medical Technology & Medical Devices
- Diagnostics & Healthcare Technology (IT)
We address all aspects of financing, that companies face from the seed- to commercialization stages. We focus on finding the best long-term financing strategy and selecting the best available financing instruments for your individual needs:
- Venture Capital
- Equity-Linked Structures
- Growth / Venture Debt
- Off-Balance Financing
- Licensing
FACTS & FIGURES
European Healthcare & Life Sciences team specialised in pre-IPO financing
WHAT WE DO
At FCF Healthcare & Life Sciences, we develop bespoke financing strategies and support our clients throughout the entire fundraising process and beyond:
Industry Expertise
- Technology Assessment
- Finetuning of Equity Story
- Pre Due-Diligence
- Science-driven Deal Selection
Finance Expertise
- Process Management
- Investor Relations
- Intelligent Market Monitoring
- Efficient Investor Communications
- Technology Assessment
- Finetuning of Equity Story
- Pre Due-Diligence
- Science-driven Deal Selection
- Process Management
- Investor Relations
- Intelligent Market Monitoring
- Efficient Investor Communications
FOCUS AREAS
- Actively managed global investor network to >1,500 investor
- Highly customized investor approach based on a proprietary investor data base
- Focus on seed to crossover rounds
- Most successful advisor in Europe
- Direct access to the European Investment Bank with >EUR 250m raised
- Access to more than 70 Growth / Venture Debt Providers (executive level)
- Joint Venture with YAFO Capital (Shanghai) Ltd.
- Specialist in fundraising, licensing and M&A transactions in the Asian market
- Access to >500 financial and strategic investors
- Collaboration with BioScience Valuation GmbH
- Leader in evidence-based commercial, R&D, and economic evaluations
- Valuable support for investment and partnering decisions
TEAM
We have built the largest venture stage dedicated team with industry and finance backgrounds in Europe:
Industry Expertise
Finance Expertise
Dr. Alexandra Goll
Advisor – Venture Capital
Dr. Axel Polack
Advisor – Science & Technology
Enno Spillner
Advisor – Capital Markets
Prof. Dr. Horst Domdey
Advisor – Science & Technology
Dr. Joachim M. Greuel
Advisor – Valuations
Arno Fuchs
Chief Executive Officer
Mathias Klozenbücher
Healthcare & Life Sciences Banking – Europe
Johannes Link
Healthcare & Life Sciences Banking – Europe
Zaid Maleh
Healthcare & Life Sciences Banking – Dubai
Sean Jiang, CFA
Healthcare & Life Sciences Banking – China
We have built the largest venture stage dedicated team with industry and finance backgrounds in Europe:
GLOBAL NETWORK
We maintain trusted relationships to leading institutional and strategic Healthcare investors as well as family offices in Europe, USA and Asia. Supported by our US and Asian partners, we can approach the right investors depending on our client’s situation. We can rely on a deep network to Life Sciences specialists (e.g. legal, valuation, licensing and IPO investment banks in the USA and Europe) to execute a seamless 360-degree long-term financing strategy. Our goal is to create value by implementing the best financing options for our clients.
| FCF Partner (New York): |
|---|
|
 |
FCF Life Sciences (Munich): |
|---|---|
|
 |
BioScience Valuation (Garmisch): |
|---|---|
|
 |
DACH ADVISORY (Dubai): |
|---|---|
|
 |
YAFO Capital (Shanghai): |
|---|---|
|
| FCF Partner (New York): |
|---|
|
|
|---|
| FCF Life Sciences (Munich): |
|
|
|---|
| BioScience Valuation (Garmisch): |
|
|
|---|
| DACH ADVISORY (Dubai): |
|
|
|---|
| YAFO Capital (Shanghai): |
|
SELECTED TRANSACTIONS
Limmatech Biologics AG
December 2023
[amount confidential]
In Ovo B.V.
August 2023
€ 40 million
numares AG
February 2022
€ 20 million
Precisis AG
September 2021
€ 20 million
Immunic AG
October 2020
€ 25 million
Limmatech Biologics AG
December 2023
[amount confidential]
Capital Markets Research
Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Healthcare & Life Sciences Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
NEWS
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 07/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 07/2024”. The Monitor is a monthly published overview of venture capital trends in
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 07/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 07/2024”. The Monitor is a monthly published overview of venture capital trends in the
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 06/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 06/2024”. The Monitor is a monthly published overview of venture capital trends in
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 06/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2024”. The Monitor is a monthly published overview of venture capital trends in the
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 05/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 05/2024”. The Monitor is a monthly published overview of venture capital trends in
